Tobias Ruck is an expert in Neurology at BG University Hospital Bergmannsheil Bochum (Germany). As of November 2026, ScienceLeadR ranks Tobias Ruck in the top 1% of experts worldwide for Autoimmune Diseases, and in the top 1% of experts in Germany for Myositis. Tobias Ruck has authored 343 publications, the most recent in 2026, and is an investigator in 12 clinical trials, 4 of them ongoing. SLR score: 1,160 (community average: 125). How the SLR is computed.

LeadR Profile

1 160 ScienceLeadR Reputation 1160
Network Map

Neurology

Subspecialties: Immunology - Biochemistry - Hematology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2013 - 2026
Source: PubMed

BG University Hospital Bergmannsheil Bochum - Director

2025 - 2026

Heinrich Heine University Düsseldorf

2020 - 2026

Düsseldorf University Hospital

2021 - 2026

Ruhr University Bochum

2025 - 2026

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 343

Citations

Citations: 5 844 1st author: 23 Last author: 53 Unique author: 3


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Targeting P2Y 12 limits T H17 accumulation in the CNS and reduces EAE progression.
PMID 42984851 — cells, pathology, clopidogrel, therapeutics, blood platelets, amplifiers, electronic, autoimmunity
Front Immunol20260
Semi-quantitative analyses of muscle magnetic resonance imaging for pattern recognition in early idiopathic inflammatory myopathies.
PMID 41854350 — dermatomyositis, muscular diseases, muscles, magnetic resonance imaging, neuromuscular diseases, myositis, diagnosis
J Neuromuscul Dis20260
Serum circulating cell-free messenger RNA profile response to risdiplam treatment in adult patients with late-onset spinal muscular atrophy.
PMID 42798856 — muscular atrophy, cells, genes, serum, atrophy, rna, messenger, biomarkers, therapeutics, muscular atrophy, spinal, liquid biopsy, spine
Brain Commun20260
Practical Guidance on Initiating and Switching Targeted Immunotherapies in Generalised Myasthenia Gravis: A German-Austrian Expert Opinion Paper.
PMID 42717567 — complement c5, complement inactivating agents, immunotherapy, therapeutics, nervous system diseases, neurologists, myasthenia gravis
Eur J Neurol20260
Investigating the role of serum IL-6 in predicting outcomes of b-cell depleting therapy in multiple sclerosis: a retrospective cohort study.
PMID 42629559 — cells, sclerosis, multiple sclerosis, serum, interleukin-6, cohort studies, biomarkers, therapeutics, nervous system diseases, b-lymphocytes
BMC Neurol20260

Clinical Studies 12

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

N/A 6
Phase 3 4
Phase 2 1
Phase 4 1

By status:

Completed 4
Active not recruiting 3
Unknown 3
Recruiting 1
Terminated 1

By type:

Interventional 6
Observational 6

By Monocentric/Multicentric:

monocentric 5
multicentric2to4 1
multicentric5to9 0
multicentricup10 6

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

4 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A study to assess the long term safety and efficacy of a subcutaneous formulation of efgartigimod in adults with active idiopathic inflammatory myopathy
2022-502851-79-00 — muscular diseases, safety, aged, myositis
Phase 3Active not recruiting2023
Understanding the Durable Effect Concept of B cell Modulating Therapies
NCT06586177 — cells, sclerosis, multiple sclerosis, tomography, optical coherence, therapeutics, b-lymphocytes, multiple sclerosis, relapsing-remitting
N/ARecruiting2021
A Natural History Study in Participants With Congenital Myasthenic Syndromes (CMS) Due to Mutations in DOK7 MUSK AGRN or LRP4
NCT06078553 — natural history, myasthenic syndromes, congenital, history, mutation
N/AActive not recruiting2024
Safety and Efficacy of ALXN1720 in Adults With Generalized Myasthenia Gravis
NCT05556096 — complement c5, safety, receptors, cholinergic, syringes, complement system proteins, acetylcholine, myasthenia gravis
Phase 3Active not recruiting2022

LeadR Networks

Main global connection map